Omeros Shares Plunge After CHMP Rejects Narsoplimab for TA-TMA
Omeros shares fell sharply after the CHMP gave a negative opinion on its drug narsoplimab for transplant-associated thrombotic microangiopathy. Company plans re-examination.
/ 220 items
#andre↓
After Re-examination, CHMP Recommends Approval of DAYBU for Rett Syndrome in the EU
Acadia’s DAYBU gets EU positive opinion for Rett syndrome; could become first approved treatment for symptoms in Europe.
Rademikibart Breakthrough Potential: Piper Sandler Sees First-in-Class Opportunity at CNTB
Rademikibart offers first-mover potential in acute asthma & COPD with major Phase 2 data coming in September 2026.
Jefferies Upgrades Tango Therapeutics to Buy, Lifts Price Target to $60 on Promising Pancreatic Cancer Data
Jefferies turned bullish on Tango Therapeutics as early cancer data and big market potential lifted its price target.
onsemi to Acquire Synaptics in $7 Billion All-Stock Deal to Accelerate Physical AI Leadership
The move strengthens edge AI, sensing, and connectivity capabilities for autonomous vehicles, robotics, and intelligent edge devices.
Apple’s Rare Mid-Cycle Price Hike: 17-54% Increases Hit Macs, iPads, and Apple TV
Evercore ISI views the move as a margin defense and maintains a bullish $365 Outperform target.